Multiple myeloma is a blood cancer accounting for 2% of cancers in the United Kingdom1. Despite available treatments, Multiple myeloma remains an incurable malignancy and is associated with significant patient burden, with patients relapsing over time2. As they relapse, patients can become refractory/resistant to treatments3.
Sanofi Genzyme Oncology is committed to the management of patients with multiple myeloma. Sarclisa®▼ (isatuximab) in combination with pomalidomide and dexamethasone (Pd) is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (PI) and have demonstrated disease progression on the last therapy4.
1. Cancer Research UK. Myeloma statistics. Available at: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/myeloma (last accessed October 2021). 2. Myeloma UK. What is myeloma? Available at: https://www.myeloma.org.uk/understanding-myeloma/what-is-myeloma (last accessed October 2021). 3. Kurtin SE (2013) Relapsed or Relapsed/Refractory Multiple Myeloma. Advancedpractitioner.com: Vol 4, No. 6, Suppl 1. Available at: https://www.advancedpractitioner.com/media/164110/005.pdf (last accessed October 2021). 4. Sarclisa Summary of Product Characteristics (SmPC). Available at: https://www.medicines.org.uk/emc/product/11535/smpc (last accessed October 2021).
Report an Adverse Event
Adverse Events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for "MHRA Yellowcard" in the Google Play or Apple App Store. Adverse Events should also be reported to the Sanofi Drug Safety Department on:
0800 0902 314
Report a Product Technical Complaint
In the case of any Product Technical Complaints, please report these by emailing the Sanofi Quality Department at UK-ProductQualityComplaints@sanofi.com